SIGA Technologies Inc
NASDAQ:SIGA
Gross Margin
SIGA Technologies Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
440.6m USD |
77%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
714.8B USD |
81%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
371.5B USD |
69%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
85%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
200.7B CHF |
73%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
179.7B CHF |
75%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
200.5B USD |
81%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
68%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
114.6B EUR |
70%
|
SIGA Technologies Inc
Glance View
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on SIGA Technologies Inc's most recent financial statements, the company has Gross Margin of 77.4%.
You don't have any saved screeners yet